Events
Sleep Apnoea CardioVascular Endpoints study (SAVE)
Planning is now being stepped up for the Sleep Apnea cardioVascular Endpoints (SAVE) trial, an international trial with Network representation which is providing valuable experience for the Network in the organisation of large-scale trials.
SAVE is designed to definitively address one of the most important questions remaining in the field of sleep medicine - namely, whether OSA causes cardiovascular events, and, if so, what level of risk reduction is achieved by OSA treatment. The Principal Investigator, ASTN CI Doug McEvoy is joined by an international investigator group to develop and implement SAVE.
Some industry sponsors are already in place, including Platinum sponsorship from Respironics Inc, and additional industry and government partnerships are currently being sought to enlarge this important trial.
